Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 121

Related Citations for PubMed (Select 23063374)

1.

Cost-minimization analysis of the treatment of patients with metastatic colorectal cancer in Greece.

Fragoulakis V, Papagiannopoulou V, Kourlaba G, Maniadakis N, Fountzilas G.

Clin Ther. 2012 Oct;34(10):2132-42. doi: 10.1016/j.clinthera.2012.09.005.

PMID:
23063374
2.

Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer.

Hoyle M, Peters J, Crathorne L, Jones-Hughes T, Cooper C, Napier M, Hyde C.

Value Health. 2013 Mar-Apr;16(2):288-96. doi: 10.1016/j.jval.2012.11.001. Epub 2013 Jan 23.

PMID:
23538180
3.

Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review.

Frank M, Mittendorf T.

Pharmacoeconomics. 2013 Mar;31(3):215-28. doi: 10.1007/s40273-012-0017-2. Review.

PMID:
23338963
4.

Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.

Mittmann N, Au HJ, Tu D, O'Callaghan CJ, Isogai PK, Karapetis CS, Zalcberg JR, Evans WK, Moore MJ, Siddiqui J, Findlay B, Colwell B, Simes J, Gibbs P, Links M, Tebbutt NC, Jonker DJ; Working Group on Economic Analysis of National Cancer Institute of Canada Clinical Trials Group; Australasian Gastrointestinal Interest Group.

J Natl Cancer Inst. 2009 Sep 2;101(17):1182-92. doi: 10.1093/jnci/djp232. Epub 2009 Aug 7.

5.

Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC).

Lawrence D, Maschio M, Leahy KJ, Yunger S, Easaw JC, Weinstein MC.

J Med Econ. 2013 Dec;16(12):1387-98. doi: 10.3111/13696998.2013.852097. Epub 2013 Oct 25.

PMID:
24102083
6.

Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer.

Shiroiwa T, Motoo Y, Tsutani K.

Mol Diagn Ther. 2010 Dec 1;14(6):375-84. doi: 10.2165/11587610-000000000-00000.

PMID:
21275455
7.

Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.

Vijayaraghavan A, Efrusy MB, Göke B, Kirchner T, Santas CC, Goldberg RM.

Int J Cancer. 2012 Jul 15;131(2):438-45. doi: 10.1002/ijc.26400. Epub 2012 Jan 3.

PMID:
21898389
8.

Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.

Asseburg C, Frank M, Köhne CH, Hartmann JT, Griebsch I, Mohr A, Osowski U, Schulten J, Mittendorf T.

Clin Ther. 2011 Apr;33(4):482-97. doi: 10.1016/j.clinthera.2011.04.010.

PMID:
21635994
9.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A.

J Clin Oncol. 2008 Dec 10;26(35):5705-12. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10.

10.

Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.

García-Foncillas J, Díaz-Rubio E.

Clin Transl Oncol. 2010 Aug;12(8):533-42. doi: 10.1007/s12094-010-0551-3. Review.

PMID:
20709651
11.

Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.

Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, Lin SR, Wang JY.

Ann Surg. 2010 Feb;251(2):254-60. doi: 10.1097/SLA.0b013e3181bc9d96.

PMID:
20010090
12.

KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective.

Blank PR, Moch H, Szucs TD, Schwenkglenks M.

Clin Cancer Res. 2011 Oct 1;17(19):6338-46. doi: 10.1158/1078-0432.CCR-10-2267. Epub 2011 Aug 1.

13.

Clinical and economic aspects of KRAS mutational status as predictor for epidermal growth factor receptor inhibitor therapy in metastatic colorectal cancer patients.

Königsberg R, Hulla W, Klimpfinger M, Reiner-Concin A, Steininger T, Büchler W, Terkola R, Dittrich C.

Oncology. 2011;81(5-6):359-64. doi: 10.1159/000334919. Epub 2012 Jan 13.

PMID:
22248908
14.

Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors.

Mancl EE, Kolesar JM, Vermeulen LC.

Am J Health Syst Pharm. 2009 Dec 1;66(23):2105-12. doi: 10.2146/ajhp090036. Review.

PMID:
19923311
15.

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD.

J Clin Oncol. 2008 Apr 1;26(10):1626-34. doi: 10.1200/JCO.2007.14.7116. Epub 2008 Mar 3.

16.

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G, Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S, Oliner KS, Rong A, Gansert J.

J Clin Oncol. 2010 Nov 1;28(31):4706-13. doi: 10.1200/JCO.2009.27.6055. Epub 2010 Oct 4.

17.

Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer.

Huang F, Xu LA, Khambata-Ford S.

Clin Cancer Res. 2012 Feb 15;18(4):1156-66. doi: 10.1158/1078-0432.CCR-11-1135. Epub 2012 Jan 31.

18.

Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer.

Saif MW, Syrigos KI, Hotchkiss S, Shanley J, Grasso J, Ferencz TM, Syrigos K, Shah MM.

Cancer Chemother Pharmacol. 2009 Dec;65(1):107-12. doi: 10.1007/s00280-009-1009-6. Epub 2009 May 5.

PMID:
19415280
19.

Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.

Tappenden P, Jones R, Paisley S, Carroll C.

Health Technol Assess. 2007 Mar;11(12):1-128, iii-iv. Review.

20.

A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer.

Lange A, Prenzler A, Frank M, Kirstein M, Vogel A, von der Schulenburg JM.

Eur J Cancer. 2014 Jan;50(1):40-9. doi: 10.1016/j.ejca.2013.08.008. Epub 2013 Sep 4. Review.

PMID:
24011538
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk